New positively charged NSAIA drug precursors of structure 1, 2a, 2b, 2c or 2d of the general formula (1, 2a, 2b, 2c or 2d) were designed and synthesized.Structure 1Compounds of structure 1, 2a, 2b, 2c, or 2d of the above formula (1, 2a, 2b, 2c or 2d) are prepared by reacting a metal salt, an organic base salt or an immobilized base salt of NSAIA and a suitable halide compound . The positive amino groups significantly increase the water solubility of the drug. The positive charge of these drug precursor amino groups will be combined with the phonophore in the phosphate head group of the membrane. Thus, the local concentrations of the membrane or skin exterior are so high that these drug precursors will readily pass from the high concentration area to the low concentration area. This binding will slightly disturb the membrane and create some space for the lipophilic portion of the drug precursor. As the membrane molecules move, the membrane is weakly cracked by the drug precursor bonds. Whereby the drug precursor is inserted into the membrane. At pH 7.4, only about 99% of the amino groups are protonated. When the amino group is not protonated, the bond between the amino group of the drug precursor and the phosphate group of the membrane is broken and the drug precursor will completely enter the membrane. The amino group of the drug precursor enters the other side of the membrane and is thus protonated, and then the drug is drawn into the cytoplasm, which is a semi-liquid concentrated aqueous solution or suspension. These drug precursors can be used for the treatment of diabetes (I and / or Type II), abnormal blood glucose and blood lipid levels, stroke, myocardial infarction and other cardiovascular diseases, Alzheimer's disease, Parkinson's disease and other neurodegenerative diseases, Inflammatory bowel disease, lupus, systemic lupus erythematosus (SLE), autoimmune hepatitis, scleroderma, Sjogren's syndrome, rheumatoid arthritis, multiple myelitis, scleroderma, Hash
